N/A
Completed N=61
AESOPS Trial 2 (AESOPS-2): Availability of Opioid Harm
Opioid Abuse
Source: ClinicalTrials.gov NCT04758637 ↗
Enrolled (actual)
61
Serious AEs
0.1%
Results posted
Oct 2025
Primary outcomePrimary: Change in Daily Average Number of 5 MME Pill Counts — -3.73; 3.89; 9.8; -4.85 Difference in estimated mean pill counts — p=0
Summary
The opioid epidemic is the largest man-made public health crisis the United States has faced. The objective of Trial 2 of the Application of Economics & Social psychology to improve Opioid Prescribing Safety (AESOPS-2) study, is to discourage unnecessary opioid prescribing by increasing the salience of negative patient outcomes associated with opioid use.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Daily Average Number of 5 MME Pill Counts |
-3.73; 3.89; 9.8; -4.85 | — |
| SECONDARY Change in Clinician-level, Pre-to-post Mean Proportion of High Dose (=> 50 MME) Patient Visits |
0.004; 0.014; 0.01; -0.09 | 0.219 |
Eligibility Criteria
Inclusion Criteria
- 1) The clinician prescribed a qualifying scheduled drug to a patient in the 12 months prior to their non-fatal or fatal overdose 2) the patient is 18 years old or older at the time of the overdose, 3) the provider practices within a health system enrolled in the study, and 4) the overdose occurs during the 12-month observation period. Qualifying prescriptions include those for one of the following scheduled drugs: opioids, benzodiazepines, muscle relaxants or sedative-hypnotics.
Exclusion Criteria
- Prescriptions to patients in hospice or with active cancer
Data sourced from ClinicalTrials.gov (NCT04758637). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.